Up-front pembro plus chemo boost survival in cervical cancerJune 4, 2023Gynecologic CancerImmunotherapyImmuno-oncologyPatient & Survivor Care
‘Huge step forward’ in advanced ovarian cancerJune 4, 2023Gynecologic CancerImmunotherapyImmuno-oncologyPatient & Survivor Care
‘Exciting’ results for cancer vaccine plus pembro in melanomaApril 21, 2023MelanomaPreventive CarePatient & Survivor CareImmunotherapyImmuno-oncology
Study gives new insight into timing of combo treatment in metastatic NSCLCApril 10, 2023Lung CancerCNS/Brain CancerImmunotherapyImmuno-oncologyPatient & Survivor CareNeuro-oncology
In metastatic NSCLC, better QoL outcomes tied to better outcomesApril 7, 2023Lung CancerPatient & Survivor CareImmunotherapy
ESMO guidelines provide ‘clear blueprint’ for managing immunotherapy toxicitiesMarch 1, 2023Immunotherapy
Adverse events linked to better survival with ICIs in melanomaDecember 30, 2022MelanomaImmuno-oncologyImmunotherapy
Discontinuing immunotherapy: Is the infusion bag half empty or half full?November 23, 2022Lung CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid CancersImmuno-oncology
A farewell to arms? Drug approvals based on single-arm trials can be flawedSeptember 19, 2022Gastrointestinal CancerPractice ManagementMixed TopicsBreast CancerCNS/Brain CancerGenitourinary CancerGynecologic Cancer
Acetaminophen linked to diminished response to immunotherapy in cancerJune 8, 2022Patient & Survivor CareImmunotherapyImmuno-oncology
Age, skin cancer risks for ICI-induced bullous pemphigoid identifiedApril 22, 2022MelanomaPatient & Survivor CareImmuno-oncologyImmunotherapy
